Progress on clinical drug trials of esophageal squamous cell carcinoma in China from 2012 to 2021
- VernacularTitle:2012—2021年中国食管鳞状细胞癌药物临床试验进展
- Author:
Dawei WU
1
;
Huiyao HUANG
1
;
Qi ZHU
2
;
Yue YU
1
;
Ziwei LI
2
;
Xinyu MENG
3
;
Jingting DU
1
;
Man GA
1
;
Shuangman MIAO
1
;
Shujun XING
1
;
Yu TANG
1
;
Ning LI
1
Author Information
1. Clinical Trials Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, P. R. China
2. 1. Clinical Trials Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, P. R. China；2. Department of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, 211198, P. R. China
3. University of Melbourne, Faculty of Medicine, Dentistry and Health Sciences, Melbourne, 3010, Australia
- Publication Type:Journal Article
- Keywords:
Esophageal neoplasms;
squamous cell carcinoma;
China;
drug;
clinical trial
- From:
Chinese Journal of Clinical Thoracic and Cardiovascular Surgery
2022;29(12):1601-1606
- CountryChina
- Language:Chinese
-
Abstract:
Objective To summarize the progress and trend on clinical drug trials of esophageal squamous cell carcinoma in China. Methods Based on the clinical drug trial registration and information disclosure platform and the drug data query system of the National Medical Products Administration, the characteristics of clinical trials, investigational drugs and listed drugs of esophageal squamous cell carcinoma in China from 2012 to 2021 were analyzed. Results From 2012 to 2021, a total of 49 clinical drug trials of esophageal squamous cell carcinoma were registered in China, accounting for 1.6% of all clinical trials of anticancer drugs. Among them, there were 39 (79.6%) trials initiated by domestic pharmaceutical enterprises, 6 (12.2%) for adjuvant and neoadjuvant treatment, and 9 (18.4%) for local treatment. There were differences in the treatment line distribution between global and domestic enterprise-initiated trials (P=0.032). The above trials covered 29 investigational drugs, including 23 (79.3%) targeted drugs, most of which targeted programmed death-1, programmed death-ligand 1 and epidermal growth factor receptor. From 2012 to 2021, there were 2 drugs for esophageal squamous cell carcinoma listed in China, both of which were approved for the first-line and second-line treatment. Conclusion Great achievements have been made in the clinical development of esophageal squamous cell carcinoma drugs in China. It is suggested that domestic enterprises increase the investment of esophageal squamous cell carcinoma, pay attention to adjuvant and local treatment, explore novel targets and drug categories, and focus on the details of pivotal trials.
